

List of Figures

Figure I. 1	Drug Delivery and Product Life Cycle Management – The Cardizem Story.....	3
Figure II. 1	Schematic diagram of Using Chamber.....	14
Figure II. 2	Membrane bilayers and IAM HPLC column.....	16
Figure II. 3	Individual Donor/Acceptor Well Assembly Before and After Incubation in PAMPA.....	17
Figure II. 4	Effect of food on absorption of Alfuzosin Hydrochloride	34
Figure II. 5	Flamel's Micropump® Technology.....	48
Figure II. 6	Scintigraphic gastric emptying curves for solid (pancake) and nutrient liquid (10% glucose). Solid empty in linear fashion following a lag phase while nutrient liquids empty in a mono-exponential manner with minimal lag.....	50
Figure II. 7	Partially unfolded dosage form modified from Curatolo and Lo. The retention arms (A), which have the ability to retain in the stomach on their own, are adhered to a receptacle (B) that holds a controlled release tablet (C). The arms induce gastroretentivity of the dosage form.....	72
Figure II. 8	Swellable systems developed by Mamajek and Moyer (a) and Urquhart and Theeuwes (b)...	74
Figure II. 9	Scanning Electron Microscope comparing Superporous Hydrogel (SPH) to a Conventional Hydrogel. (A) Surface of Conventional Hydrogel (B) Surface of a typical Superporous hydrogel (C) Cross- section of a typical Superporous Hydrogel	76
Figure II. 10	Different geometric forms of unfoldable systems proposed by Caldwell et al.	80
Figure II. 11	On the left, superporous hydrogel in its dry (a) and water-swollen (b) state. On the right, schematic illustration of the transit of superporous hydrogel. Gutierrez-Rocca et al.....	82
Figure II. 12	Hydrodynamically balanced system (HBS). The gelatinous polymer barrier formation results from hydrophilic polymer swelling. Drug is released by diffusion and erosion of the gel barrier	84
Figure II. 13	Schematic representation of “floating pill” proposed by Ichikawa (a). The penetration of water into effervescent layer leads to a CO ₂ generation and makes the system float (b).	86
Figure II. 14	Gas-generating systems. Schematic monolayer drug delivery system.....	86
Figure II. 15	Intra Gastric Floating Gastrointestinal Drug Delivery Device.....	87
Figure II. 16	Inflatable gastrointestinal delivery system	87
Figure II. 17	Intragastric osmotically controlled drug delivery system	88
Figure II. 18	(A) Multiple-unit oral floating drug delivery system. (B) Working principle of effervescent floating drug delivery system.....	90
Figure II. 19	Schematic presentation of working of a triple-layer system. (A) Initial configuration of triple-layer tablet. (B) On contact with the dissolution medium the bismuth layer rapidly dissolves and matrix starts swelling. (C) Tablet swells and erodes. (D) and (E) Tablet erodes completely.....	91
Figure II. 20	Pictorial presentation of working of effervescent floating drug delivery system based on ion exchange resin.....	94
Figure II. 21	Working principle of hydrodynamically balanced system	96
Figure II. 22	Intragastric floating tablets. (A) Sheth and Tossounion, 1979. (B) Sheth and Tossounion, 1979	97
Figure II. 23	Schematic illustration of the barrier formed by a raft-forming system	99
Figure II. 24	Schematic localization of a high density system in the stomach.....	99
Figure II. 25	Mechanism for retention of bioadhesive microspheres in the human stomach. A capsule containing the bioadhesive microspheres is administered with water and the released microspheres float on the fluid in the stomach. During the process of gastric emptying, a proportion of the bioadhesive microspheres adheres to the stomach wall to provide gastroretention.....	101
Figure III. 1	Chromatogram of the blank sample for determination of assay of Alfuzosin Hydrochloride	131
Figure III. 2	Chromatogram of the standard sample for determination of assay of Alfuzosin Hydrochloride	132
Figure III. 3	Chromatogram of the test sample for determination of assay of Alfuzosin Hydrochloride...	132
Figure III. 4	Chromatogram of the blank sample for determination of dissolution of Alfuzosin Hydrochloride	136
Figure III. 5	Chromatogram of the standard sample for determination of dissolution of Alfuzosin Hydrochloride	137

List of Figures

Figure III. 6	Chromatogram of the test sample for determination of dissolution of Alfuzosin Hydrochloride	137
Figure III. 7	Chromatogram of the blank sample for determination of related substance of Alfuzosin Hydrochloride	140
Figure III. 8	Chromatogram of the standard sample for determination of related substance of Alfuzosin Hydrochloride	140
Figure III. 9	Chromatogram of the test sample for determination of related substance of Alfuzosin Hydrochloride	141
Figure III. 10	Chromatogram of the test sample for determination of related substance of Alfuzosin Hydrochloride	141
Figure IV. 1	Schematic diagram of Rat intestinal Perfusion Study	148
Figure IV. 2	Photograph of Single Pass Intestinal Perfusion in rat intestine	148
Figure IV. 3	DSC thermogram of Alfuzosin Hydrochloride	155
Figure IV. 4	FT-IR of Alfuzosin Hydrochloride	156
Figure IV. 5	X-Ray Diffractogram of Alfuzosin Hydrochloride	156
Figure IV. 6	TGA graph of Alfuzoisn Hydrochloride	158
Figure IV. 7	Dissolution Profile of Marketed Formulation (Alfuzosin Hydrochloride Extended Release Tablet 10mg)	163
Figure IV. 8	Chromatogram of the stock solution (SS) of Alfuzosin Hydrochloride determined during SPIP study in rat 1	165
Figure IV. 9	Chromatogram of the adsorption sample (AS) of Alfuzosin Hydrochloride determined during SPIP study in rat 1	165
Figure IV. 10	Chromatogram of the Test sample (TS) of Alfuzosin Hydrochloride determined during SPIP study in rat 1	165
Figure IV. 11	Chromatogram of the stock solution (SS) of Phenol Red determined during SPIP study in rat 1	166
Figure IV. 12	Chromatogram of the adsorption sample (AS) of Phenol Red determined during SPIP study in rat 1	166
Figure IV. 13	Chromatogram of the Test sample (TS) of Phenol Red determined during SPIP study in rat 1	166
Figure IV. 14	Chromatogram of the stock solution (SS) of Alfuzosin Hydrochloride determined during SPIP study in rat 2	167
Figure IV. 15	Chromatogram of the adsorption sample (AS) of Alfuzosin Hydrochloride determined during SPIP study in rat 2	167
Figure IV. 16	Chromatogram of the Test sample (TS) of Alfuzosin Hydrochloride determined during SPIP study in rat 2	167
Figure IV. 17	Chromatogram of the stock solution (SS) of Phenol Red determined during SPIP study in rat 2	168
Figure IV. 18	Chromatogram of the adsorption sample (AS) of Phenol Red determined during SPIP study in rat 2	168
Figure IV. 19	Chromatogram of the Test sample (TS) of Phenol Red determined during SPIP study in rat 2	168
Figure IV. 20	Chromatogram of the stock solution (SS) of Alfuzosin Hydrochloride determined during closed loop method in rat 1	169
Figure IV. 21	Chromatogram of the Test sample (TS) of Alfuzosin Hydrochloride in duodenum determined during closed loop method in rat 1	170
Figure IV. 22	Chromatogram of the Test sample (TS) of Alfuzosin Hydrochloride in ileum determined during closed loop method in rat 1	170
Figure IV. 23	Chromatogram of the Test sample (TS) of Alfuzosin Hydrochloride in duodenum determined during closed loop method in rat 2	170
Figure IV. 24	Chromatogram of the Test sample (TS) of Alfuzosin Hydrochloride in ileum determined during closed loop method in rat 2	171
Figure IV. 25	Chromatogram of the stock solution (SS) of Phenol Red determined during closed loop method in rat 1	171
Figure IV. 26	Chromatogram of the Test sample (TS) of Phenol Red in duodenum determined during closed loop method in rat 1	171

List of Figures

Figure IV. 27	Chromatogram of the Test sample (TS) of Phenol Red in ileum determined during closed loop method in rat 1.	172
Figure IV. 28	Chromatogram of the Test sample (TS) of Phenol Red in duodenum determined during closed loop method in rat 2.	172
Figure IV. 29	Chromatogram of the Test sample (TS) of Phenol Red in ileum determined during closed loop method in rat 2.	172
Figure V. 1	Dissolution profile of Batches with different ratio of polymers in 0.01 N HCL/paddle/ 50 rpm	214
Figure V. 2	Dissolution profile of B. No 15 (with magnesium stearate) in various media/paddle/50 rpm.....	215
Figure V. 3	Dissolution profile with and without Magnesium stearate (B.No 15 vs B.No 17 in 6.8 pH phosphate Buffer/paddle/50 rpm.	215
Figure V. 4	Comparative Dissolution profile of Marketed formulation vs B.No 23 in 0.01 N HCL/50 rpm/paddle	217
Figure V. 5	Comparative Dissolution profile of Marketed formulation vs B.No 23 in 6.8 pH phosphate Buffer/50 rpm/paddle.....	217
Figure V. 6	Comparative Dissolution profile of B.No 02 (1.13%) vs B.No 03 (2.1%) in 0.01 N HCL/50 rpm/paddle	226
Figure V. 7	Comparative Dissolution profile of B.No 02 vs Marketed Formulation in 0.01 N HCL/50 rpm/paddle	228
Figure V. 8	Comparative Dissolution profile of B. No 02 vs Marketed Formulation in 4.5 pH acetate buffer/50 rpm/paddle.....	228
Figure V. 9	Comparative Dissolution profile of B.No 02 vs Marketed Formulation in 6.8 pH phosphate Buffer/50 rpm/paddle.....	229
Figure V. 10	Gastric Retention time of Dummy tablets of B.No 23 in Healthy volunteer (PK-A-153) under Fasted condition.....	231
Figure V. 11	Gastric Retention time of Dummy tablets of B.No 23 in Healthy volunteer (PK-E-108) under Fasted condition.....	232
Figure V. 12	Gastric Retention time of Dummy tablets of B.No 23 in Healthy volunteer (PK-B-071) under Fed condition	233
Figure V. 13	Gastric Retention time of Dummy tablets of B.No 23 in Healthy volunteer (PK-B-653) under Fed condition	235
Figure V. 14	Mean plasma concentration vs time curve of B.No 23 (Test) vs Marketed Formulation (Reference) in Fasted state (N=8)	237
Figure V. 15	Mean plasma concentration vs time curve of B.No 23 (Test) vs Marketed Formulation (Reference) in Fed state (N=8).....	237
Figure V. 16	Comparative Dissolution profile of B.No 023 vs Marketed Formulation in 4.5 pH acetate Buffer/50 rpm/paddle.....	238
Figure V. 17	Comparative Dissolution profile of B.No 023 vs Marketed Formulation in pH 3.0 acid base Buffer/50 rpm/paddle.....	239
Figure V. 18	Comparative Dissolution profile of B.No 023 in various media/50 rpm/paddle.....	240
Figure V. 19	Scheme of interaction of Eudragit RS with various anion species (a = Cross linking: decelerated oscillation, hindered water flux, low permeability; b = Surface sealing: decelerated oscillation, hindered water flux, low permeability; c = "Active water carrier": permanent oscillation, induced water flux, high permeability).	245
Figure V. 20	Drug release mechanism of Eudragit RS membranes (Fc = Coulomb force)	246
Figure VI. 1	Dissolution profile in B.No. 06 in 0.1 N HCL/Basket/100rpm.....	261
Figure VI. 2	Gastric Retention time of Dummy tablets of B.No 06 in Healthy volunteer (PK-D-737) under Fasted condition.....	263
Figure VI. 3	Gastric Retention time of Dummy tablets of B.No 06 in Healthy volunteer (PK-G-085) under Fasted condition.....	264
Figure VI. 4	Gastric Retention time of Dummy tablets of B.No 06 in Healthy volunteer (PK-G-098) under Fed condition	266
Figure VI. 5	Gastric Retention time of Dummy tablets of B.No 06 in Healthy volunteer (PK-G-105) under Fed condition	267
Figure VII. 1	Swelling Capacity of POLYOXTM Resins with Molecular Weight	276
Figure VII. 2	The chemical structure of polyvinylpyrrolidone (povidone) Mr (111.1)x	278

List of Figures

Figure VII. 3	Viscosity curves for the soluble Kollidon grades in water (capillary viscometer, 25 °C).....	280
Figure VII. 4	Comparative Dissolution profile of Marketed Formulation vs B. No. 01 and B. No. 02 containing Polyethylene Oxide (WSR 303) alone (20% vs. 40%) in 0.01N HCl/paddle/50 rpm	285
Figure VII. 5	Comparative Dissolution profile of B. No 16 and B. No 47 with Marketed Formulation in different media (0.01 N HCl, pH 3 acid base buffer, 4.5 pH acetate buffer, 6.8 pH phosphate buffer)	289
Figure VII. 6	Gastric Residence time of Dummy formulation of B.No 47 in Healthy Volunteer (PK-E-395) under Fasted State.....	290
Figure VII. 7	Gastric Residence time of Dummy formulation of B.No 47 in Healthy Volunteer (PK-E-428) under Fasted State	291
Figure VII. 8	Gastric Residence time of Dummy formulation of B.No 47 in Healthy Volunteer (PK-C-636) under Fed State	293
Figure VII. 9	Gastric Residence time of Dummy formulation of B.No 47 in Healthy Volunteer (PK-E-018) under Fed State	294
Figure VII. 10	Gastric Residence time of Dummy formulation of B.No 47 in Healthy Volunteer (PK-F-685) under Fed State	296
Figure VII. 11	Mean plasma concentration vs time curve of B.NO 16 (Test) vs Marketed formulation (Reference) in Fed state	299
Figure VII. 12	Semi logarithmic plasma concentration vs time curve of B.NO 16 (Test) vs Marketed formulation (Reference) in Fed state.....	299
Figure VII. 13	Mean plasma concentration vs time curve of B.NO 47 (Test) vs Marketed formulation (Reference) in Fasted state.....	302
Figure VII. 14	Semi logarithmic plasma concentration vs time curve of B.NO 47 (Test) vs Marketed formulation (Reference) in Fasted state	303
Figure VII. 15	Mean plasma concentration vs time curve of B.NO 47 (Test) vs Marketed formulation (Reference) in Fed state	306
Figure VII. 16	Semi logarithmic plasma concentration vs time curve of B.NO 47 (Test) vs Marketed formulation (Reference) in Fed state.....	306
Figure VII. 17	Comparative dissolution profile of Alfuzosin HCl ER tablet (Marketed Formulation Vs B.No 016) in different media and with different rpm and apparatus.....	313
Figure VII. 18	Swelling Capacity of Non-Ionic Water Soluble Polymers.....	315
Figure VII. 19	Comparative Dissolution profile of B.No 147 and B.No 158 with Marketed Formulation in different media (0.01 N HCl, 4.5 pH acetate buffer, 6.8 pH phosphate buffer).....	326
Figure VII. 20	Mean plasma Concentration vs Time curve of B.NO 147 (Test) vs Marketed formulation (Reference) in Fasted state.....	330
Figure VII. 21	Semi logarithmic plasma Concentration vs Time curve of B.NO 147 (Test) vs Marketed formulation (Reference) in Fasted state	330
Figure VII. 22	Mean plasma Concentration vs Time curve of B.NO 147 (Test) vs Marketed formulation (Reference) in Fed state	333
Figure VII. 23	Semi logarithmic plasma Concentration vs Time curve of B.NO 147 (Test) vs Marketed formulation (Reference) in Fed state.....	334
Figure VII. 24	Mean plasma concentration vs time curve of B.NO 158 (Test) vs Marketed formulation (Reference) in Fasted state.....	336
Figure VII. 25	Semi logarithmic plasma concentration vs time curve of B.NO 158 (Test) vs Marketed formulation (Reference) in Fasted state	337
Figure VII. 26	Mean plasma concentration vs time curve of B.NO 158 (Test) vs Marketed formulation (Reference) in Fed state	339
Figure VII. 27	Semi logarithmic plasma concentration vs time curve of B.NO 158 (Test) vs Marketed formulation (Reference) in Fed state.....	340
Figure VII. 28	Level B correlation of B.No 147 and B.No 158 in Fasted and Fed state	340
Figure VII. 29	Comparative characterization of swelling nature of Batch No. 16 Vs Batch No. 47 Vs Marketed formulation Vs Batch No. 147 Vs Batch No. 158 at different time intervals.	349
Figure VII. 30	Comparative Swelling properties of B.No 16 vs B.No 47 vs B.No 147 vs B.No 158	350
Figure VII. 31	Level B correlation of B. No 147, B. No 159 and B. No 158 in fasted and Fed state.....	351